Form 4: Cingulate Inc. CLO and CCO Nilay Patel Granted 30,000 Stock Options

Cingulate Inc.'s Chief Legal Officer and Chief Compliance Officer, Nilay Dahyabhai Patel, was granted 30,000 stock options with an exercise price of $4.51, vesting over four years.

Summary

• Nilay Dahyabhai Patel, Cingulate Inc.'s Chief Legal Officer (CLO) and Chief Compliance Officer (CCO), was granted 30,000 stock options.
• The stock options have an exercise price of $4.51 per share.
• The grant date for these options is July 8, 2025.
• The options are set to expire on July 8, 2035.
• The vesting schedule for the options is as follows: 25% vests on the one-year anniversary of the grant date, and the remaining shares vest in substantially equal monthly installments over the subsequent 36-month period.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive for aligning management and shareholder interests, though it is a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to a key executive like the CLO and CCO aligns their financial interests with those of shareholders, incentivizing long-term company performance.
• Providing an equity stake through options can serve as a valuable tool for executive retention.

Risks

• The ultimate value of the stock options is contingent upon Cingulate Inc.'s common stock price exceeding the $4.51 exercise price at the time of exercise.
• Future volatility in the company's stock price could impact the realized value of these options for the executive.

Future Outlook

The vesting schedule indicates that the executive will gain the right to purchase shares over a four-year period, aligning their future financial incentives with the company's long-term performance and growth.

Industry Context

Granting stock options is a common practice in the pharmaceutical and biotechnology industries to attract, retain, and incentivize key executives, aligning their compensation with company growth and shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a standard practice across most industries, including pharmaceuticals, for aligning management incentives with shareholder interests.
• The specific number of options (30,000) and exercise price ($4.51) would require comparison against similar roles and company sizes within the industry to assess if it is above, below, or in line with typical compensation packages, but this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of stock options to an executive constitutes a transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with shareholder value creation.
• Employees: May signal stability and a commitment to executive retention, potentially boosting morale.

Next Steps

• The options will begin vesting on the one-year anniversary of the grant date (July 8, 2026).
• Subsequent vesting will occur in monthly installments over the following 36 months.
• The executive may choose to exercise vested options at any point before the expiration date of July 8, 2035.

Key Dates

Keywords

Cingulate Inc., CING, Stock Options, Executive Compensation, Nilay Patel, Form 4, Insider Transaction, Equity Grant, CLO, CCO